Stockreport

Immunovant Announces Pricing of $550 Million Common Stock Financing

Immunovant, Inc.  (IMVT) 
PDF Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical- [Read more]